Clinical briefing for providers on Androderm's permanent discontinuation. Timeline, prescribing implications, alternative formulations, patient transition guidance, and tools for 2026.
Androderm (testosterone transdermal system) has been permanently discontinued by Allergan/AbbVie. This is not a temporary shortage with an expected resolution date — the product is no longer manufactured, and no generic or biosimilar alternative exists.
For providers managing patients on testosterone replacement therapy (TRT), this briefing covers the timeline, prescribing implications, available alternatives, and practical tools to support patient transitions.
The FDA's Orange Book continues to list Androderm (NDA 020489) but with no currently marketed formulations.
The loss of Androderm eliminates the only FDA-approved testosterone transdermal patch from the U.S. formulary. Key considerations for prescribers include:
Androderm provided a distinct clinical niche: steady-state testosterone delivery with minimal secondary exposure risk (since the medication was covered by the patch adhesive). This profile was particularly valued for:
There is no FDA-approved generic testosterone patch and no other brand-name patch on the market. Providers must transition patients to a different formulation class entirely.
Many insurance plans had specific prior authorization criteria for Androderm. When transitioning patients to alternative formulations, be aware that:
As of 2026, the following testosterone replacement formulations remain available:
When transitioning patients, cost sensitivity is critical — particularly for uninsured or underinsured patients:
Patients without insurance or with high-deductible plans should be directed toward discount card programs (GoodRx, SingleCare, RxSaver) and manufacturer copay programs where applicable. For detailed savings strategies, see our provider savings guide for helping patients save money on testosterone therapy.
The testosterone transdermal patch market remains vacant. While the FDA continues to accept ANDAs (Abbreviated New Drug Applications) for generic products, no applications for a generic testosterone patch are currently known to be under review.
The broader TRT market is moving toward more convenient delivery systems — oral formulations, autoinjectors, and long-acting injectables — which may explain the lack of commercial interest in reviving the patch form factor.
Providers should assume the discontinuation is permanent and update their treatment algorithms accordingly. For patients who specifically valued the patch delivery method, generic testosterone gel with thorough secondary exposure counseling is the closest available analog.
The Androderm discontinuation highlights the vulnerability of single-source medications. For clinicians managing TRT patients, the priority now is ensuring smooth transitions to alternative formulations with appropriate dose monitoring and follow-up.
If you need help supporting patients through this change, Medfinder for Providers offers tools to check pharmacy stock and streamline the process of finding available testosterone products.
For additional clinical context, see our provider guide on helping patients find testosterone therapy.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
